Turn Therapeutics Inc.

Turn Therapeutics Inc. develops non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases and fungal infections. Its lead investigational drug candidate, GX-03, targets moderate-to-severe eczema and onychomycosis using a polyhexanide formulation. The company also develops medical devices based on this formulation for acute wound management, dermatitis care, and antimicrobial wound dressings. Additionally, it conducts exploratory research on a thermostable intranasal vaccine platform. The company's business model centers on licensing its medical devices to commercial healthcare partners, including Medline and MiMedx, while directing internal resources toward clinical drug development.

The company is based in Westlake Village, California, and is incorporated in Delaware. It operates primarily within the United States, where it conducts clinical trials, while preparing foundational clinical activities in select international jurisdictions. Turn Therapeutics relies on a lean internal workforce alongside third-party contractors, vendors, and commercial distribution partners to carry out its development and manufacturing activities.

Summary of the business section of Turn Therapeutics's latest annual report, written by StockData.